453 related articles for article (PubMed ID: 27028439)
1. Cardiology Patient Pages: Antidotes for Bleeding Caused by Novel Oral Anticoagulants.
Pollack CV
Circulation; 2016 Jan; 133(2):e18-9. PubMed ID: 27028439
[No Abstract] [Full Text] [Related]
2. [Not Available].
Själander S; Själander A
Lakartidningen; 2018 Dec; 115():. PubMed ID: 30512136
[No Abstract] [Full Text] [Related]
3. Management of Bleeding With Non-Vitamin K Antagonist Oral Anticoagulants in the Era of Specific Reversal Agents.
Ruff CT; Giugliano RP; Antman EM
Circulation; 2016 Jul; 134(3):248-61. PubMed ID: 27436881
[TBL] [Abstract][Full Text] [Related]
4. [Antidote treatment during use of direct anticoagulants].
Rutherford OW; König MSS; Risnes K; Raouf N; Atar D; Ghanima W
Tidsskr Nor Laegeforen; 2018 Feb; 138(3):. PubMed ID: 29411596
[No Abstract] [Full Text] [Related]
5. [Treatment with inhibitors of new oral direct anticoagulants in patients with severe bleedings or urgent surgical procedures. The new dabigatran antidote: the place of idarucizumab in clinical practice].
Boda Z
Orv Hetil; 2016 Mar; 157(12):443-50. PubMed ID: 26971644
[TBL] [Abstract][Full Text] [Related]
6. Coordinating emergent procedures after andexanet alfa.
Culbreth SE; Sylvester KW; Rimsans J; Connors JM
Am J Hematol; 2019 Oct; 94(10):E278-E282. PubMed ID: 31342554
[No Abstract] [Full Text] [Related]
7. [NOAC: Real-life data and the role of antidotes for the treatment of bleeding].
Darius H
Med Klin Intensivmed Notfmed; 2017 Mar; 112(2):99-104. PubMed ID: 28144725
[TBL] [Abstract][Full Text] [Related]
8. Management of direct oral anticoagulants-associated bleeding in the trauma patient.
von Heymann C; Rosenthal C; Kaufner L; Sander M
Curr Opin Anaesthesiol; 2016 Apr; 29(2):220-8. PubMed ID: 26934279
[TBL] [Abstract][Full Text] [Related]
9. Idarucizumab and factor Xa reversal agents: role in hospital guidelines and protocols.
Huisman MV; Fanikos J
Am J Emerg Med; 2016 Nov; 34(11S):46-51. PubMed ID: 27697438
[TBL] [Abstract][Full Text] [Related]
10. [Peri-Interventional Management of Direct Oral Anticoagulants - Balancing Benefits and Risks].
Dülgeroglu J; Schmidt D
Praxis (Bern 1994); 2018 Apr; 107(9-10):485-493. PubMed ID: 29690851
[No Abstract] [Full Text] [Related]
11. [State of the art: Direct oral anticoagulants and transfusion].
Martin AC; Godier A; Smadja DM; Mauge L; Fischer AM
Transfus Clin Biol; 2017 Sep; 24(3):154-159. PubMed ID: 28673500
[TBL] [Abstract][Full Text] [Related]
12. Security profile of direct anticoagulants. Preferred use in atrial fibrillation.
Roldán Rabadán I; Alonso de Leciñana M; Barba Martín R; Páramo Fernández JA;
Clin Investig Arterioscler; 2019; 31(6):263-270. PubMed ID: 31213323
[TBL] [Abstract][Full Text] [Related]
13. Clinical implications of reversal agents for direct oral anticoagulants.
Monagle S; Eikelboom JW; Ng KH; Bhagirath VC
Future Cardiol; 2017 Mar; 13(2):153-159. PubMed ID: 28198201
[TBL] [Abstract][Full Text] [Related]
14. Reversal of anticoagulants: an overview of current developments.
Greinacher A; Thiele T; Selleng K
Thromb Haemost; 2015 May; 113(5):931-42. PubMed ID: 25832311
[TBL] [Abstract][Full Text] [Related]
15. Intravenous thrombolysis for stroke in patients taking non-VKA oral anticoagulants: an update.
Cappellari M; Bovi P
Thromb Haemost; 2015 Aug; 114(2):440-4. PubMed ID: 25809649
[No Abstract] [Full Text] [Related]
16. [Monitoring options and reversal agents for oral anticoagulants].
Thorup SB; Husted SE; Vang ML
Ugeskr Laeger; 2014 Apr; 176(9):. PubMed ID: 25096568
[TBL] [Abstract][Full Text] [Related]
17. Management of Elective Surgery and Emergent Bleeding with Direct Oral Anticoagulants.
Kaatz S; Mahan CE; Nakhle A; Gunasekaran K; Ali M; Lavender R; Paje DG
Curr Cardiol Rep; 2017 Oct; 19(12):124. PubMed ID: 29064044
[TBL] [Abstract][Full Text] [Related]
18. [New oral anticoagulants in patients with atrial fibrillation in a urban health center].
Rodríguez Pérez L; Capilla Lozano F; Gallego Fuentes R; Buitrago F
Med Clin (Barc); 2016 Mar; 146(6):280-1. PubMed ID: 26343157
[No Abstract] [Full Text] [Related]
19. Andexxa--an antidote for apixaban and rivaroxaban.
Med Lett Drugs Ther; 2018 Jun; 60(1549):99-101. PubMed ID: 29913471
[No Abstract] [Full Text] [Related]
20. [Not Available].
Simeon L; Wuillemin WA
Ther Umsch; 2016; 73(10):561-566. PubMed ID: 28045358
[No Abstract] [Full Text] [Related]
[Next] [New Search]
